Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

Abstract Background Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targe...

Celý popis

Podrobná bibliografia

Vydané v:	Neuro-oncology (Charlottesville, Va.) Ročník 25; číslo 11; s. 2058 - 2071
Hlavní autori:	Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 02.11.2023
Predmet:	Glioblastoma - pathology Humans Immunotherapy, Adoptive - methods Killer Cells, Natural Neoplasm Recurrence, Local - drug therapy Receptors, Chimeric Antigen Recurrence human clinical trial NK cells glioblastoma CAR in HER2 phase I first adoptive immunotherapy
ISSN:	1522-8517, 1523-5866, 1523-5866
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!